Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bio-Techne (TECH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Bio-Techne (TECH) over the last 17 years, with Q4 2025 value amounting to 13.54%.

  • Bio-Techne's EBITDA Margin rose 104000.0% to 13.54% in Q4 2025 from the same period last year, while for Dec 2025 it was 8.59%, marking a year-over-year decrease of 27900.0%. This contributed to the annual value of 7.53% for FY2025, which is 59200.0% down from last year.
  • Latest data reveals that Bio-Techne reported EBITDA Margin of 13.54% as of Q4 2025, which was up 104000.0% from 11.75% recorded in Q3 2025.
  • Over the past 5 years, Bio-Techne's EBITDA Margin peaked at 3647.25% during Q3 2022, and registered a low of 1.42% during Q2 2025.
  • Over the past 5 years, Bio-Techne's median EBITDA Margin value was 14.86% (recorded in 2022), while the average stood at 197.69%.
  • Per our database at Business Quant, Bio-Techne's EBITDA Margin soared by 36229300bps in 2022 and then plummeted by -36331500bps in 2023.
  • Bio-Techne's EBITDA Margin (Quarter) stood at 31.53% in 2021, then dropped by -22bps to 24.56% in 2022, then plummeted by -38bps to 15.34% in 2023, then tumbled by -80bps to 3.14% in 2024, then skyrocketed by 331bps to 13.54% in 2025.
  • Its EBITDA Margin was 13.54% in Q4 2025, compared to 11.75% in Q3 2025 and 1.42% in Q2 2025.